Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Sarcoma 2Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 10Adenocarcinoma of Lung 7Carcinoma 3Neoplasm Metastasis 2Neoplasms 1Glioblastoma 1EGFR-mutant Non-small Cell Lung Cancer 1Bronchial Neoplasms 1

Interventions

pembrolizumab 3Paclitaxel 3Nivolumab 2Drug Therapy 2Bevacizumab 2Azacitidine 2vocimagene amiretrorepvec 1ulixertinib 1spartalizumab 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1regorafenib 1pazopanib 1motexafin gadolinium 1fludarabine 1erythromycin propionate-N-acetylcysteinate 1epacadostat 1depatuxizumab mafodotin 1cobimetinib 1cediranib 1cc-486 1carboxyamido-triazole 1capmatinib 1bemcentinib 1aflibercept 1abiraterone 1abemaciclib 1Uncertainty 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × capmatinib × Thoracic × Clear all
NCT01324479 2020-12-19

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

Novartis

Phase 1 Completed
131 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡